Companies · Healthtech

Invicta Medical, Inc.

SANTA CLARA · Healthtech · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Invicta Medical, Inc. — recommendation, valuation, rhythm, risks.
$55.2M
Total raised · real
4
Rounds
1.4×
Latest step-up
Top 9%
Sector rank · raised
Series B
Latest stage · inferred · Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Invicta Medical, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the healthtech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.79× the median modeled value of Series B Healthtech companies in 2022–2024 (98 peers) — value vs value, same stage and era.
At-risk
  • Last raise 3.7 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Healthtech

Invicta Medical, Inc. is one of 2138 Healthtech companies tracked from SANTA CLARA. By capital raised it ranks among the largest (ahead of 92% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
26
Investors (latest)
2022-10-11
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2016-07-01 Raised $5.5M (real) Modeled valuation $124M (est)$5.5M$124MSeries A2016Series B · 2017-12-20 Raised $21M (real) Modeled valuation $520M (est)$21M$520MSeries B2017Series B · 2021-10-29 Raised $3.7M (real) Modeled valuation $60M (est)$3.7M$60MSeries B2021Series B · 2022-10-11 Raised $18M (real) Modeled valuation $215M (est)$18M$215MSeries B2022Series B · 2022-10-11 Raised $25M (real) Modeled valuation $296M (est)$25M$296MSeries B2022+$21M+$3.7M+$18M+$25MCumulative $73M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.5M · 2016
Series B$21.0M · 2017
Series B extension$3.7M · 2021
Series B extension$18.1M · 2022
Series B extension$25.0M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$295.9M
Base estimate est.
$58.7M
Conservative case
$736.2M
Upside case
$138.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.

Series A · modeled $123.5M · 2016-07-012016Series B · modeled $520.5M · 2017-12-20Series B · modeled $60.2M · 2021-10-29Series B · modeled $214.8M · 2022-10-11Series B · modeled $295.9M · 2022-10-112022
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.38×/yr
Annual markup
1.67×/yr upside case
3.7 yr
Elapsed time used
3.7 yr actual, capped for stale marks
healthtech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
19 mo
Avg between rounds
$8.8M/yr
Capital velocity
10.0 yr
On record since
2016
First round
5
Rounds on file
How it compares to the market

Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 12× above median
This company$55.2M
Sector median$4.5M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.4× above median
This company$25.0M
Sector median$18.3M
Modeled value — vs sector median (estimate, all stages) 8.8× above median
This company$295.9M
Sector median$33.8M

Raised more than 92% of sector peers (real $). Modeled value above 89% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #19 of 98.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Casana Care, Inc. · Series B Raised $56.4M · modeled $607.4M (est)Mendel Health Inc. · Series B Raised $52.7M · modeled $570.4M (est)Bicycle Health Inc. · Series B Raised $61.4M · modeled $492.2M (est)Brave Health, Inc. · Series B Raised $38.6M · modeled $485.3M (est)Flume Health, Inc. · Series B Raised $35.9M · modeled $445.6M (est)Healthy America, LLC · Series B Raised $31.0M · modeled $435.5M (est)Moxe Health Corp · Series B Raised $34.8M · modeled $403.8M (est)Kintsugi Mindful Wellness, Inc. · Series B Raised $25.0M · modeled $370.1M (est)Invoq Health, Inc. · Series B Raised $41.5M · modeled $362.2M (est)Folx Health, Inc. · Series B Raised $59.3M · modeled $355.4M (est)Recuro Health, Inc. · Series B Raised $44.2M · modeled $339.7M (est)Orchard Healthcare, Inc. · Series B Raised $34.8M · modeled $338.6M (est)Invicta Medical, Inc. (this company) Raised $55.2M · modeled $295.9M (est)Invicta Medical, Inc.
CompanyStageRaised · realValue · estvs peer med.
Casana Care, Inc.Series B$56.4M$607.4M3.68×
Mendel Health Inc.Series B$52.7M$570.4M3.45×
Bicycle Health Inc.Series B$61.4M$492.2M2.98×
Brave Health, Inc.Series B$38.6M$485.3M2.94×
Flume Health, Inc.Series B$35.9M$445.6M2.70×
Healthy America, LLCSeries B$31.0M$435.5M2.64×
Moxe Health CorpSeries B$34.8M$403.8M2.45×
Kintsugi Mindful Wellness, Inc.Series B$25.0M$370.1M2.24×
Invoq Health, Inc.Series B$41.5M$362.2M2.19×
Folx Health, Inc.Series B$59.3M$355.4M2.15×
Recuro Health, Inc.Series B$44.2M$339.7M2.06×
Orchard Healthcare, Inc.Series B$34.8M$338.6M2.05×
Invicta Medical, Inc. this companySeries B$55.2M$295.9M1.79×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.5M2016-07-01$24.9M$123.5M85%
Series B$21.0M2017-12-20$116.7M$520.5M90%
Series B$3.7M2021-10-29$20.7M$60.2M90%
Series B$18.1M2022-10-11$100.7M$214.8M90%
Series B$25.0M2022-10-11$138.8M$295.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.5M2016-07-01
    • First recorded raise — entered as Series A.
    • 32 investors on this round.
  2. Series B$21.0M2017-12-20
    • Raised 18 mo later, in step with the ~14 mo sector norm.
    • Round 3.8× larger than the prior — scaling up.
    • 6 investors on this round.
  3. Series B$3.7M2021-10-29
    • Raised again after 46 mo — slower than the ~14 mo sector norm.
    • Round 5.6× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  4. Series B$18.1M2022-10-11
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 4.9× larger than the prior — scaling up.
    • 18 investors on this round.
  5. Series B$25.0M2022-10-11
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× larger than the prior — scaling up.
    • 26 investors on this round.
Intelligence
2024 ~Q2
Modeled next raise · ~19mo cadence
$34.4M
Modeled next size est.range $25.0M$55.1M
1.4×
Last step-up
$8.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Andrew Perlman14 other2021-10
Jason Camm4 other2021-10
Erik Engelson3 other2022-10
Konstantinos Alataris2 other2021-10
Seth Winterroth2 other2021-10
Dr. Ismail Kola2022-10
Harold T. Kent2016-07
Jason T. Camm2016-07
Rick O'Connor2021-10
Steven T. Kent2016-07
William T. Deihl2016-07
Registry & provenance

Invicta Medical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1675786
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Sirona Medical, Inc.HealthtechSeries B$53.0M$637.8Mnetwork1 shared operator · same sector · same stage
DeVoro Medical Inc.HealthtechSeries B$26.5M$446.1Mnetwork1 shared operator · same sector · same stage
Turquoise Health Co.HealthtechSeries B$55.2M$241.3Msame sector · same stage
Integrated Care Partners, Inc.HealthtechSeries B$55.0M$145.7Msame sector · same stage
Heartbeat Health, Inc.HealthtechSeries B$53.0M$164.6Msame sector · same stage
Inspire Medical Systems, Inc.HealthtechSeries B$52.5M$309.8Msame sector · same stage
Clinicient, IncHealthtechSeries B$52.1M$427.6Msame sector · same stage
Folx Health, Inc.HealthtechSeries B$59.3M$355.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Invictus Medical, Inc.HealthtechSeed$34.9M94%
InSite Health, Inc.HealthtechSeed$34.8M87%
Inscope Medical Solutions, Inc.HealthtechPre-Seed$10.4M87%
Truvic Medical, Inc.HealthtechSeries A$132.9M86%
iFirst Medical Technologies, Inc.HealthtechPre-Seed$5.2M85%
Atropos Health IncHealthtechSeries B$232.3M85%
Navinata Health, Inc.HealthtechPre-Seed$19.7M85%
InterRad Medical, Inc.HealthtechSeries A$82.4M85%
Frequently asked
How much funding has Invicta Medical, Inc. raised?
Invicta Medical, Inc. has raised approximately $55.2M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Invicta Medical, Inc.'s estimated valuation?
Provath's modeled valuation for Invicta Medical, Inc. is approximately $295.9M (modeled range $58.7M–$736.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Invicta Medical, Inc. at?
Invicta Medical, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Oct 11.
What does Invicta Medical, Inc. do and where is it based?
Invicta Medical, Inc. operates in the Healthtech sector, based in SANTA CLARA.
Explore related

See where Invicta Medical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Invicta Medical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.